Two Genentech Inc. executives who left the biotech powerhouse last year — Dr. Gwen Fyfe and Roy Hardiman — joined the board of Pharmacyclics Inc., and a third Genenexer joined the Sunnyvale drug developer as a vice president.
Fyfe, Hardiman and Dr. Eric Hedrick are among a growing list of people who have landed elsewhere since Swiss drugmaker Roche bought out Genentech in a $47 billion deal in March 2009.
Fyfe, Hardiman and Dr. Eric Hedrick are among a growing list of people who have landed elsewhere since Swiss drugmaker Roche bought out Genentech in a $47 billion deal in March 2009.
No comments:
Post a Comment